IDO2 and neoplasm: By combining the advantages of local RT and systemic tumor rejection via synergistic X-ray-induced in situ vaccination and indoleamine 2,3-dioxygenase inhibition, MOF-based nanoplatforms may overcome some of the limitations of RT and checkpoint blockades in cancer treatment.